MAP2K7 and cancer: High-frequency mutation of AHNAK2 correlated with poor prognosis of cancer patients, promoting epithelial–mesenchymal transition and activating oncogenic pathways, such as MAPK, Wnt, and MEK signaling pathways (Zhang et al., 2023).